Doctors Warn Against Microdosing GLP-1 Drugs for Weight Loss

A growing global trend of individuals 'microdosing' GLP-1 receptor agonists, such as semaglutide, has sparked serious concern among medical professionals. Users are taking fractional, self-administered doses of popular weight-loss drugs to curb appetite while trying to avoid common side effects like nausea. However, clinical researchers warn that there is absolutely no scientific data supporting the safety or long-term efficacy of sub-therapeutic dosing.

The practice has gained rapid traction on social media platforms, partially driven by severe global shortages of brand-name medications like Ozempic and Wegovy. Patients also turn to microdosing to stretch their expensive prescriptions or compounded alternatives over longer periods. Medical experts point out that altering prescribed dosage schedules disrupt the medication's designed metabolic pathway, which can lead to unpredictable hormone spikes and muscle loss.

The trend is highly relevant in India, where access to genuine GLP-1 medications is growing alongside a rise in unbranded generic formulations. Indian doctors emphasize that self-medicating with unauthorized doses bypasses crucial medical supervision, increasing the risk of pancreatitis, thyroid issues, and severe nutritional deficiencies. Regulatory bodies are urged to monitor online spaces where informal medical advice on self-dosing is heavily promoted.